Antibody-Drug Conjugates: Not Quite Worked Out Yet (opens in new tab)

I’ve written several times here over the years about antibody-drug conjugates (most recently here and here), and it’s a field that has seen some ups and downs. Recent years have been more of an upswing, honestly, but I’m starting to wonder if that might be coming to an end. It certainly seems to be doing so over at Pfizer, as reported here at Endpoints. They bought a company specializing in these (Seagen) in 2023 for a cool $43 billion as well as doing other deals in this space, but things ha...